Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Aug 28;155(4):159-161.
doi: 10.1016/j.medcli.2020.04.018. Epub 2020 May 27.

Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection

[Article in English, Spanish]
José Luis Callejas Rubio  1 , Juan de Dios Luna Del Castillo  2 , Javier de la Hera Fernández  3 , Emilio Guirao Arrabal  4 , Manuel Colmenero Ruiz  5 , Norberto Ortego Centeno  6
Affiliations
Case Reports

Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection

[Article in English, Spanish]
José Luis Callejas Rubio et al. Med Clin (Barc). .

Abstract

Introduction: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.

Patients: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.

Results: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.

Discussion: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.

Keywords: Coronavirus COVID-19; Cytokine release synddrome; Hemofagocítico; Hemophagocytic; Síndrome de liberación de citocinas.

PubMed Disclaimer

References

    1. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. McGonagle D., Sharif K., O’Regan A., Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. 102537. - DOI - PMC - PubMed
    1. Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. - DOI - PMC - PubMed
    1. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2. - DOI - PMC - PubMed
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. - DOI - PMC - PubMed

MeSH terms